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ABSTRACT
Melatonin plays different physiological functions ranging from the regulation of 
circadian rhythms to tumor inhibition, owing to its antioxidant, immunomodulatory 
and anti-aging properties. Due to its pleiotropic functions, melatonin has been shown 
to elicit cytoprotective processes in normal cells and trigger pro-apoptotic signals 
in cancer cells. The therapeutic potential of melatonin analogues prompted us to 
investigate the in vitro and in vivo antitumor activity of new melatonin derivatives 
and explore the underlying molecular mechanisms. The experiments revealed that 
the new melatonin analogues inhibited the growth of melanoma and breast cancer 
cells in a dose- and time-dependent manner. In addition, our results indicated that 
melatonin derivative UCM 1037 could induce apoptosis in melanoma and breast cancer 
cells, as well as cell necrosis, in MCF-7.  Together, apoptosis and necrosis could be two 
possible mechanisms to explain the cytotoxic effect of the melatonin analogue against 
cancer cells. The suppression of tumor growth by the melatonin analogues was further 
demonstrated in vivo in a xenograft mice model. A decrease in the activation of MAPK 
pathway was observed in all cancer cells following UCM 1037 treatment. Overall, 
this study describes a promising antitumor compound showing antiproliferative and 
cytotoxic activity in melanoma and breast cancer cells.
INTRODUCTION
The N-acetyl-5-methoxytryptamine, or melatonin, is 
an indolic hormone mainly synthesized and secreted by the 
pineal gland from the essential amino acid tryptophan [1]. 
In addition, there is also evidence for melatonin production 
in other organs, including the retina, gastrointestinal 
tract, skin, bone marrow, and immune system cells [2]. 
Melatonin production is regulated by photoperiod as its 
synthesis and secretion are repressed by light and induced 
in response to darkness [3].
Melatonin plays pleiotropic roles in maintaining 
health and preventing disease [4]. A plethora of 
pathological disorders have been associated with the 
reduction of circulating melatonin levels, including aging, 
metabolic syndrome, type 2 diabetes, immune diseases, 
hypertension, mood and cognitive disorders, and cancer 
[5–8].
Over the last decades, significant research efforts 
have been devoted to defining the role of melatonin in 
the pathogenesis of cancer and its possible therapeutic 
application. It has been shown that melatonin, under both 
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in vitro and in vivo conditions, inhibits the growth of some 
cancer cells [9–11], although its role and mechanism of 
action are still controversial. Besides its antiproliferative 
role in cancer cells, melatonin can also exert cell protection 
functions, acting as a scavenger for reactive oxygen and 
reactive nitrogen species and activating cytoprotective 
enzymes [12–14].
Melatonin can exert its multiple actions by various 
receptor-dependent and receptor-independent mechanisms 
[15]. Accordingly, melatonin interacts with different 
cellular components, including intracellular proteins, 
nuclear membrane receptors, and cell membrane receptors. 
Two membrane receptors, MT1 (formerly called Mel1a or 
ML1A) and MT2 (formerly called Mel1b or ML1B) were 
cloned [16, 17] and pharmacologically characterized [18]. 
They are both members of the superfamily of G-protein 
coupled receptors, traditionally considered to function 
as monomers, but they can also act as homodimers and 
heterodimers. When they act as monomers, the receptor 
signaling inhibits protein kinase A (PKA) pathway and 
CREB phosphorylation. The MT1 receptor also modulates 
phosphorylation of mitogen-activated protein kinase 1/2 
(MAPK1/2) and extracellular signal–regulated kinase 
1/2 (ERK1/2) [19]. As homo and heterodimers human 
MT1 and MT2 receptors alter phospholipase C (PLC) 
and protein kinase C (PKC) pathways [20]. In addition, 
melatonin can cross cell membranes exerting several 
receptor-independent effects [21]. These include the 
activation of different cascades and/or ion channels 
resulting in cAMP decrease, PLC, PKC, MAP kinase 
and phosphatidylinositol 3 kinase (PI3K)/Akt pathways 
activation, Ca2+-activated K+ as well as voltage-gated Ca2+ 
channels modulation [22].
The effects of melatonin have been studied 
in numerous types of tumors, leading to the general 
conclusion that melatonin inhibits cell proliferation and 
induces apoptosis in most tumor cell lines and reduces 
tumor growth in cancer murine models. Moreover, 
melatonin suppresses tumor metastases by regulating 
cell adhesion, extracellular matrix remodeling, epithelial-
mesenchymal transition, cytoskeleton reorganization and 
angiogenesis [11].
The effects of melatonin on different tumors 
are quite diverse, ranging from antioxidant, immune-
modulatory and enzyme regulatory, to regulation of 
various kinases and transcription factors or via activation 
of its G-protein coupled MT1/MT2 receptors. Radiolabeled 
ligands and selective MT1 and MT2 melatonin receptor 
agonists and antagonists, are currently used as tools for 
studying melatonin functions and some receptor agonists 
have also been approved for clinical use, mainly to treat 
sleep disorders or major depression [23, 24].
Herein, we studied new synthetic indole melatonin 
analogues for their ability to inhibit proliferation and 
induce apoptosis in cancer cell lines and to reduce tumor 
growth in a cancer mouse model.
RESULTS
Human receptor binding characterization of the 
new melatonin derivatives
The new melatonin analogues (UCM 976, UCM 
1032, UCM 1033, UCM 1037) were designed starting 
from previous indole melatonin receptor ligands 
replacing their 5-methoxy group with a moiety known to 
induce some MT1 selectivity such as the more lipophilic 
phenylbutoxy one (Table 1).
The melatonin derivatives were evaluated for their 
binding affinity and intrinsic activity at human MT1 
and MT2 receptors stably transfected in NIH3T3 mouse 
fibroblasts and the results are reported in Table 2.
All the new compounds displayed affinity for MT1 
receptor in the nanomolar range and modest selectivity 
(approximately 10-fold) with respect to MT2 receptor. In 
particular, MT1 and MT2 binding affinity measures for 
UCM 976 are comparable to those previously reported 
[25] for receptors expressed in CHO cells. Compared 
with the corresponding N-anilinoethylamide ligand [26], 
carrying the same phenylbutyloxy side chain, this indole 
derivative has a slightly lower MT1 selectivity. As expected 
from structure-activity relationships for indole receptor 
ligands, insertion of a lipophilic substituent in position 
2 increases binding affinity at both receptor subtypes, as 
well as intrinsic activity. Indeed, functional assays showed 
full agonist behavior at both melatonin receptor subtypes, 
except UCM 976 which can be considered as a partial 
agonist at the MT2 receptor.
Antiproliferative and cytotoxic effects of 
melatonin analogues on cancer cell lines
Melatonin has been shown to inhibit growth of a 
wide variety of cancer cells, including hormone-dependent 
and hormone-independent tumors. In this study, we chose 
to investigate the antiproliferative and cytotoxic activity 
of melatonin analogues in hormone-dependent (breast 
cancer) and hormone-independent (melanoma) cancer 
types. DX3 and WM-115 melanoma, as well as MCF-7 
and MDA-MB231 breast cancer cells were first assessed 
for MT1/2 expression by Western blot analysis (Figure 1). 
MT1/2 receptors were detectable in all the cell lines 
examined. NIH3T3 mouse fibroblasts stably transfected 
with MT1 (NIH3T3-1A) and MT2 receptor (NIH3T3-
1B) were used as positive controls for MT1 and MT2 
respectively, wild type NIH3T3 cell lysate was loaded as 
a negative control.
The antiproliferative effects of the synthesized 
compounds were evaluated in the cancer cell lines by the 
XTT assay that detects the cellular metabolic activities. 
DX3, WM-115, MCF-7 and MDA-MB231 cells were 
seeded in 96-well plates and 24 hours later were treated 
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Figure 1: MT1/2 receptors expression in different cell lines. Western blot analysis showing the expression of MT1/2 receptors in 
NIH3T3, NIH3T3-1A, NIH3T3-1B, DX3, WM-115, MCF-7 and MDA-MB231 cells. The assay was performed on 30 µg of protein extract 
from each cell line. Tubulin is shown as a loading control.
Table 1: Chemical structures of melatonin and of the new synthesized melatonin analogues
Compound Structure cLogPa
Melatonin
N
H
MeO
NH
O
0.71
UCM 976
N
H
O
NH
O
3.55
UCM 1032
N
H
O
NH
Br
O
4.26
UCM 1033
N
H
O
NH
O
5.28
UCM 1037
N
H
O
NH
I
O
4.26
aCalculated logP values (cLogP) were calculated using ChemBioDraw Ultra 14.0 (Cambridge Soft, Cambridge, MA, USA).
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with 0.1% dimethyl sulfoxide (DMSO) dissolved in 
cultured medium or with melatonin (10−5–10−3 M), UCM 
976, UCM 1032, UCM 1033 and UCM 1037 (10−6–10−4 
M) in 0.1% DMSO and cultured for 24, 48 and 72 hours. 
The XTT assay revealed that most compounds had an 
antiproliferative effect in a dose- and time-dependent 
manner (Figures 2 and 3). In particular, UCM 1033 and 
UCM 1037 10−4 M showed the maximum effect in DX3 
Figure 2: Cell viability of melanoma cells treated with different doses of melatonin analogues. DX3 and WM-115 cells were 
seeded as described in Materials and Methods and treated with 0.1% DMSO, melatonin (MLT), UCM 976, UCM 1032, UCM 1033 and 
UCM 1037 dissolved in 0.1% DMSO at the indicated doses expressed in molarity (M). DX3 cell viability was evaluated by XTT assay after 
24 (panel A), 48 (panel B) and 72 hours (panel C). Panels D–F show WM-115 cell viability  evaluated as described above after 24, 48 and 
72 hours respectively. Graphic bars represent percentage of living cells in each sample. The results have been normalized to 0.1% DMSO 
treated cells and are the means of three independent experiments ± s.d. *P-value < 0.001 versus 0.1% DMSO treated cells.
Table 2: Human melatonin receptor binding affinity and relative intrinsic activity of melatonin 
analogues
MT1 MT2
pKi (± s.d.)  IAr (± s.d.) pKi (± s.d.) IAr (± s.d.)
Melatonin 9,623 ± 0,037 1,000 ± 0,001 9,66 ± 0,017 1,000 ± 0,001
UCM 976 8,46 ± 0,041 0,702 ± 0,06 7,30 ± 0,064 0,392 ± 0,022
UCM 1032 8,73 ± 0,131 0,942 ± 0,01 7,87 ± 0,106 0,759 ± 0,076
UCM 1033 8,62 ± 0,214 0,997 ± 0,003 7,73 ± 0,160 0,859 ± 0,015
UCM 1037 8,86 ± 0,148 0,930 ± 0,044 7,72 ± 0,140 0,776 ± 0,011
Oncotarget68342www.impactjournals.com/oncotarget
cells reducing cell viability to 40% and 37% after 48 
hours and to 25% and 22% after 72 hours respectively 
compared to DMSO treated cells (Figure 2B and 2C). The 
same melatonin analogues caused an even more marked 
decrease of cell proliferation in WM-115 cells, with UCM 
1033 and UCM 1037 10−4 M reducing cell number to 
21% and 23% after 48 hours and to 14% and 10% after 
72 hours respectively compared to DMSO treated cells 
(Figure 2E and 2F). Melatonin did not inhibit significantly 
cell proliferation of melanoma cells at the same dose.
The effects of melatonin and its analogues on cell 
proliferation were also investigated on two human breast 
cancer cell lines (Figure 3).  The XTT assay showed 
that all melatonin derivatives had an antiproliferative 
effect on MCF-7 cells in a dose- and time-dependent 
manner, although to different extents (Figure 3A–3C). In 
particular, UCM 1032 10−4 M showed the maximum effect 
reducing cell viability to 14% compared to DMSO treated 
cells after 72 hours. This difference was significant also 
versus melatonin 10−3 M. Similar results were obtained 
in MDA-MB231 cells (Figure 3D–3F). The reduction of 
cell viability estimated as the percentage relative to the 
mean of absorption obtained from the 0.1% DMSO treated 
cells after 72 hours was 37%, 14%, 26% and 31% for 
UCM 976, UCM 1032, UCM 1033 and UCM 1037 (10−4 
M) respectively. Cell viability reduction was significant 
compared to both DMSO and melatonin (10−3 M) treated 
cells.
UCM 1037 was selected to assay its cytotoxicity 
in DX3, WM-115, MCF-7 and MDA-MB231 cells by 
Annexin-V and Propidium Iodide staining for apoptosis. 
Cells were seeded in Petri dishes and 24 hours later 
were treated with 0.1% dimethyl sulfoxide (DMSO) 
dissolved in cultured medium or with UCM 1037 (10−4 
M) in 0.1% DMSO. After 24, 48 and 72 hours, cells were 
stained with Annexin-V/PI for the quantitative analysis 
Figure 3: Cell viability of breast cancer cells treated with different doses of melatonin analogues. MCF-7 and MDA-
MB231 cells were seeded as described in Materials and Methods and treated with 0.1% DMSO, melatonin (MLT), UCM 976, UCM 1032, 
UCM 1033 and UCM 1037 dissolved in 0.1% DMSO at the indicated doses expressed in molarity (M). After 24 (panel A), 48 (panel B) 
and 72 hours (panel C) MCF-7 cell viability was evaluated by XTT assay. Panels D–F show MDA-MB231 cell viability  evaluated as 
described above after 24, 48 and 72 hours respectively. Graphic bars represent percentage of living cells in each sample. The results have 
been normalized to 0.1% DMSO treated cells and are the means of three independent experiments ± s.d. *P-value < 0.001 versus 0.1% 
DMSO treated cells.
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of apoptotic and necrotic cells [27]. Cytofluorimetric 
analysis revealed that 88% of DX3 cells treated with 
UCM 1037 10−4 M were Annexin-positive/PI-positive 
after 72 hours of treatment (Figure 4A), implicating that 
the vast majority of UCM 1037 treated cells were in late 
apoptosis/secondary necrosis. WM-115 cells treated as 
described above exhibited a time-dependent cytotoxicity 
induced by UCM 1037 10−4 M, with 22%, 52% and 
65% of Annexin-positive cells after 24, 48 and 72 hours 
respectively (Figure 4B). MCF-7 cells showed a different 
Figure 4: Detection of apoptosis and necrosis by Annexin-V/Propidium Iodide assay. DX3 (panel A), WM-115 (panel B), 
MCF-7 (panel C) and MDA-MB231 (panel D) cells were treated with 0.1% DMSO or with UCM 1037 10−4 M dissolved in 0.1% DMSO. 
After 24, 48 and 72 hours cells were simultaneously stained with Alexa Fluor-488-Annexin-V and Propidium Iodide and analyzed by 
flow cytometry to determine apoptosis and necrosis as described in Materials and Methods. One representative experiment out of three 
performed with similar results is shown in the cytograms. The white bars of the graphs below the cytograms represent the percentage of 
apoptotic cells (A+/PI− ; A+/PI+), while the red  bars represent the percentage of necrotic cells (A−/PI+) treated as described above.
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pattern of cytotoxicity induced by the melatonin analogue, 
with 80% of Annexin-negative and PI-positive cells after 
72 hours, representative of necrotic death in MCF-7 
cells treated with UCM 1037 (Figure 4C). MDA-MB231 
cells subjected to the same treatments exhibited a time-
dependent cytotoxicity induced by UCM 1037, with 18%, 
38% and 44% of Annexin-positive cells after 24, 48 and 
72 hours respectively (Figure 4D). Microscopic images 
of cells were also taken and are shown in Supplementary 
Data (Supplementary Figures 1 and 2).
Oncostatic effect of melatonin analogues on a 
melanoma mouse model
The experiments described in the previous 
paragraph demonstrated that UCM 1033 and UCM 1037 
melatonin analogues were the most effective compounds 
in suppressing cancer cell growth in melanoma cells. 
For this reason, DX3 cell line was chosen to perform in 
vivo experiments to test oncostatic effects of UCM 1033 
and UCM 1037 on a human melanoma xenograft mouse 
model.
Data displayed in Figure 5 show that UCM 1033 
melatonin analogue significantly inhibited melanoma 
tumor growth by 40%, while UCM 1037 inhibition 
of cancer growth reached 90% compared to vehicle 
treated mice. The same dose of melatonin did not induce 
significant tumor growth suppression.
Antiproliferative effects of UCM 1037 in cell 
clones expressing MT1 and MT2 receptors
In order to address the hypothesis that UCM 1037 
antiproliferative activity is, at least in part, mediated by 
melatonin receptors, NIH3T3 mouse fibroblasts, as well 
as NIH3T3-1A and NIH3T3-1B cell clones expressing 
MT1 and MT2 respectively, were treated with 0.1% DMSO 
dissolved in cultured medium or with 10−4 M UCM 1037 
in 0.1% DMSO and cultured for 24, 48 and 72 hours. The 
XTT assay revealed that while wild type NIH3T3 cell 
proliferation was not significantly affected by UCM 1037, 
the melatonin analogue had an antiproliferative effect in a 
time-dependent manner on NIH3T3-1A and NIH3T3-1B 
cell clones (Figure 6A). This decrease in cell proliferation 
was not due to cell death since cell viability was greater 
than 92% in both NIH3T3 clones following 72 hours of 
treatment (Figure 6B).
Effects of UCM 1037 on protein expression
The correlation between the occurrence of cell 
death and the changes in the expression levels of different 
proteins involved in apoptosis and in MT1/2 mediated 
response induced by UCM 1037 was next investigated. 
Specifically, MAPK and Akt signaling pathways have 
been chosen for their key roles in the antiproliferative 
effects of melatonin [28–30]. The expression of molecules 
regulating the apoptotic pathway, such as Bcl-2, Bax and 
caspase 3 has also been analyzed.
A short term time course was performed in DX3, 
WM-115, MCF-7 and MDA-MB231 cells treated 
with DMSO 0, 1% or UCM 1037 10−4 M. Western blot 
analysis showed that phosphorylated Akt at serine 473 
(p-Akt) increased by 80% in DX3 cells treated with 
UCM 1037 compared to DMSO control, while p-MAPK 
levels decreased up to 50% upon UCM 1037 treatment 
(Figure 7A). Western blot analysis in WM-115 melanoma 
cells confirmed that UCM 1037 significantly inhibited 
phosphorylation of MAPK (up to 30% compared to 
DMSO treated cells) but not Akt (Figure 7B). The 
expression of MAPK and Akt was not altered by UCM 
1037 in both melanoma cell lines.
Figure 5: Antitumor activity of melatonin analogues in a xenograft mouse model. DX3 xenograft mice were injected s.c. with 
5% DMSO (control), melatonin (MLT), UCM 1037, UCM 1033 16mg/kg in 5% DMSO every day for three weeks. All animals were then 
anesthetized and tumors removed and weighted. (A) Tumor xenografts from one of three independent experiments are shown. (B) Values 
of tumor mass are expressed as the mean ± s. d. (n = 3). *P < 0.001, compared with the control group.
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Next, we detected the expression of the pro-
apoptotic proteins caspase-3 and Bax, as well as the 
anti-apoptotic protein Bcl-2. Treatment with UCM 1037 
effectively induced caspase-3 cleavage in DX3 cells 
(Figure 7A), but not in WM-115 cells (Figure 7B). In 
contrast, Bcl-2 expression did not change in DX3 cells, 
while it decreased by 65% in WM-115 cells after one hour 
of treatment with UCM 1037. No changes in Bax levels 
were observed in both cell lines. 
To further confirm that the Akt and MAPK signaling 
pathways are involved in the UCM 1037 mediated 
inhibition of proliferation in breast cancer cells, the 
phosphorylated forms of the above mentioned proteins 
were analyzed in MCF-7 (Figure 8A) and MDA-MB231 
cells (Figure 8B). Western blot analysis revealed that in 
both breast cancer cell lines p-Akt decreased dramatically 
upon treatment with UCM 1037, up to 20% and 10% 
in MCF-7 and MDA-MB231 respectively. Similarly, 
p-MAPK levels fast decreased after treatment with 
UCM 1037. Bcl-2 expression did not change in both 
breast cancer cells, while cleaved caspase-3 strongly 
increased only in MDA-MB231 cells upon treatment with 
UCM 1037. Bax levels did not change after UCM 1037 
treatment in both breast cancer cell lines.
DISCUSSION
Melatonin is a key element of the homeostatic 
mechanisms of the organism and it is involved in 
regulating a large number of physiological processes. 
Based on the plethora of biological roles played by 
melatonin, we can expect to find, among its analogues, 
potential drugs for treatment of metabolic and endocrine 
disorders as well as oncological diseases. Accordingly, 
melatonin receptors have emerged as appealing therapeutic 
targets for anticancer therapies over a wide range of cancer 
types [24]. Indeed, in the past decades several molecules 
which specifically bind to melatonin receptors have been 
tested for their role in the prevention or treatment of 
pathological conditions [31–33].
In this study, four indole melatonin analogues were 
synthesized and their antiproliferative and pro-apoptotic 
Figure 6: Cell viability of NIH3T3 cells treated with UCM 1037. NIH3T3, NIH3T3-1A and NIH3T3-1B cells were treated with 
0.1% DMSO or with UCM 1037 10-4 M dissolved in 0.1% DMSO. After 24, 48 and 72 hours cell viability was evaluated by XTT assay (A) 
and Trypan blue dye exclusion assay (B). In panel A bar graph represents the percentages of living cells normalized to 0.1% DMSO treated 
cells. In panel B bar graph represents the percentage of dead cells in each sample. Data are the means of three independent experiments ± 
s.d. *P-value < 0.001 versus 0.1% DMSO treated cells.
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effects were analyzed in melanoma and breast cancer cell 
lines.  According to the results of the cell viability assays, 
all the tested compounds (10−4 M) showed significant 
antiproliferative effects in all cell lines after 72 hours 
of treatment, even if only UCM 1037 demonstrated 
significant antiproliferative effect at the 10−6 M 
concentration in DX3, MCF-7 and MDA-MB231 cells. In 
breast cancer cell lines, UCM 1037 significantly inhibited 
cell viability in a time-dependent manner, although to a 
lesser extent than in DX3 cells. MCF-7 and MDA-MB231 
cells displayed maximum inhibition of cell proliferation 
upon UCM 1032 treatment, but this melatonin analogue 
failed to significantly reduce cell number at the 10−6 M 
concentration. As previously reported [9, 10, 30, 34], 
millimolar concentrations of melatonin inhibited cancer 
cell viability, while lower concentrations had no effect 
on cancer cell proliferation. While melatonin has the 
highest binding affinity for its MT1 and MT2 receptors, 
it showed no or minimal antiproliferative activity. On the 
contrary, all melatonin derivatives caused a  reduction of 
cell viability at various extents in the different cancer cell 
lines examined. This discrepancy between antiproliferative 
activity and affinity at melatonin receptors could arise 
from different reasons. First, melatonin has a range of 
known effects, either receptor-mediated or not,  which 
protect cells form different damaging factors [35]. Thus, 
the cytostatic activity of melatonin derivatives could just 
emerge as the result of MT1/2 mediated antiproliferative 
effects and the lack of melatonin non-receptor mediated 
cytoprotective effects. On the other hand, activity on DX3 
and WM-115 melanoma cells was significantly higher for 
compounds having a substituent (halogen or phenyl) at the 
position 2 of the indole nucleus and paralleled the increase 
in compound lipophilicity. Thus, while antiproliferative 
activity may be attributed to the receptor-mediated 
actions of these compounds, the hypothesis that it may be 
modulated by compound ability to interact with lipophilic 
compartments of the cells and/or be due to some, yet 
uncharacterized, off target cannot be ruled out. Melatonin 
has been previously shown to have oncostatic effects on 
melanoma in vitro and in vivo [36–37], yet melanoma cells 
proliferation can be differentially suppressed by melatonin 
upon different conditions, such as synchronized  versus 
unsynchronized growth, cell lineage, melatonin receptor-
dependent and independent mechanisms [36, 38].
Since the cytotoxic effect of melatonin seems 
to occur only in specific types of tumors and is not as 
widespread as its oncostatic action [9], we tested the 
hypothesis that UCM 1037 could exert a pro-apoptotic 
activity on cancer cell lines. The flow cytometric analysis 
after Annexin-V/PI staining confirmed the cytotoxic 
activity of UCM 1037 on DX3, WM-115, MCF-7 and 
Figure 7: Time course of protein expression in UCM 1037 melanoma treated cells. DX3 (panel A) and WM-115 (panel B) cells 
were treated with DMSO 0.1% or UCM 1037 10-4 M for 0, 10, 30, 60, 120, 240 minutes and then subjected to Western blot analysis. Blots 
are shown for p-Akt, Akt, p-MAPK, MAPK, Bcl-2, caspase-3, Bax proteins with their corresponding tubulin controls. The black triangle 
points to the cleaved caspase-3 form. One representative blot is shown of three independent experiments. Bar charts show quantification of 
p-Akt, p-MAPK, Bcl-2, and Bax protein levels in DMSO (white bars) and UCM 1037 (black bars) treated cells. Densitometric data were 
normalized versus tubulin and results are presented as relative percentage of protein levels at 0 hours. Each bar represents the mean ± s.d. of 
three independent experiments.
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MDA-MB231 cells, although the cell death mechanisms 
activated by the melatonin analogue were different in the 
cell lines that we considered. In particular, UCM 1037 
exhibited a pro-apoptotic activity in melanoma cells 
as well as in MDA-MB231 breast cancer cells, while 
it induced mostly necrosis in MCF-7 cells. Overall our 
results indicated that UCM 1037 may induce different cell 
death pathways to wield its cytotoxic effect in  diverse 
cancer cells.
We next investigated the anti-tumor activity of UCM 
1033 and UCM 1037 (16 mg/Kg) in vivo and we revealed 
that melatonin analogues  suppressed tumor growth of 
DX3 melanoma cells xenograft mice model to a much 
greater extent than melatonin administered at the same 
dose.  The antiproliferative effect of UCM 1037 was higher 
than that of UCM 1033, while the two compounds did not 
substantially differ in the in vitro cell viability tests on 
DX3 cells. This may be due to differences in lipophilicity, 
which may result in differential tissue distribution. 
However, the possibility that the two compounds may bind 
an off target with different affinities, and that this putative 
off target has different relevance in the in vitro and in vivo 
experiments, respectively, cannot be ruled out. Overall our 
findings point out the antiproliferative and pro-apoptotic 
properties of the newly synthetized melatonin analogue 
both in vitro and in vivo.
These findings prompted us to further investigate 
the effects of UCM 1037 in the signaling pathways 
involved in antiproliferative and pro-apoptotic actions 
of the melatonin derivative. Since both MT1 and MT2 
are implicated in controlling cellular growth in response 
to melatonin, we evaluated UCM 1037 antiproliferative 
effects in NIH3T3-1A and NIH3T3-1B clones compared 
to wild type NIH3T3 fibroblasts (Figure 6). Cell viability 
assays revealed that both clones  displayed a significant 
inhibition of cell proliferation compared to NIH3T3 
cells, indicating that the antiproliferative activity of the 
melatonin analogue is receptor-dependent. Moreover, 
these experiment also demonstrated that UCM 1037 10−4M 
is not cytotoxic in normal cells, since cell viability was not 
affected in NIH3T3 treated clones.
As previously stated, due to the lipophilic nature 
of UCM 1037 (Table 1), receptor-independent effects 
could also be envisaged, with multiple signaling leading 
to modulation of different cascades. Several studies using 
different cell types indicated that MAPK and Akt signaling 
pathways are associated with melatonin-mediated 
antiproliferative actions [28–30]. We highlighted that 
the melatonin analogue can trigger and/or inhibit these 
pathways differently in the cell lines examined. According 
to our data, UCM 1037 inhibits MAPK phosphorylation 
in all cell lines, although to different extents. MAPK/ERK 
Figure 8: Time course of protein expression in UCM 1037 breast cancer treated cells. MCF-7 (panel A) and MDA-MB231 cells (panel 
B) cells were treated with DMSO 0.1% or UCM 1037 10-4 M for 0, 10, 30, 60, 120, 240 minutes and then subjected to Western blot analysis. Blots 
are shown for p-Akt, Akt, p-MAPK, MAPK, Bcl-2, caspase-3, Bax proteins with their corresponding tubulin controls. The black triangle points to the 
cleaved caspase-3 form. One representative blot is shown of three independent experiments. Bar charts show quantification of p-Akt, p-MAPK, Bcl-2, 
and Bax protein levels in DMSO (white bars) and UCM 1037 (black bars) treated cells. Densitometric data were normalized versus tubulin and results 
are presented as relative percentage of protein levels at 0 hours. Each bar represents the mean ± s.d. of three independent experiments.
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pathway is known to be modulated by melatonin receptors 
and melatonin antiproliferative and anti-metastatic 
activities have been  proved to involve multiple pathways 
including inhibition of p38 MAPK [30, 39]. Our results 
suggest that the inhibition of MAPK phosphorylation 
following UCM 1037 administration is indeed triggered by 
the melatonin analogue and this action might be mediated 
by the melatonin receptors, which are expressed in the cell 
lines examined (Figure 1).
The Akt pathway was affected quite differently 
in the diverse cell lines: p-Akt increased in DX3 
cells, remained unaffected in WM-115 cells, while 
it dramatically decreased in breast cancer cell lines. 
Actually, melatonin was previously shown to inhibit Akt 
phosphorylation in MCF-7 [29] and MDA-MB231 cells 
[28]; though it was recently observed that melatonin could 
upregulate the PI3K/Akt pathway in other model systems 
[40, 41], including a melanoma cell line [42].
The mechanisms of melatonin-dependent cell death 
in cancer are still controversial and data presented in this 
paper confirm some of the discrepancies observed by 
others [43]. In fact, although an increase in the apoptotic 
fraction of cells was induced by UCM 1037 in DX3, 
WM-115 and, to a lesser extent, in MDA-MB231 cells, 
no effects were visible on Bax levels up to 72 hours after 
the compound administration (Figures 7, 8 and data not 
shown). In contrast, cleaved forms of caspase-3 were 
detected in DX3 and MDA-MB231 cells after one hour, 
indicating that UCM 1037 induces apoptosis by activating 
a caspase cascade in these cell lines. Caspase-3 was not 
cleaved in WM-115 cells, but the anti-apoptotic Bcl-2 
protein expression was inhibited following UCM 1037 
treatment. However, no changes in Bcl-2 protein levels 
were observed in the other cell lines. These results contrast 
with the findings of other studies showing that melatonin 
modulates Bcl-2/Bax balance in cancer cells [44–47].
A different mechanism must be envisaged for 
MCF-7 cells, where the expression of caspase-3 is still 
controversial. We and others [48] were able to detect the 
uncleaved form of this caspase in Western blots, but most 
studies report that MCF-7  do not express caspase-3. It has 
been demonstrated that even caspase-3-deficient MCF-7 
cells can undergo apoptosis following a variety of stimuli 
[49], nevertheless Annexin V/PI staining demonstrated 
that  UCM 1037 is able to induce necrosis in the MCF-
7 cells. For this reason we suggest that apoptosis and 
necrosis could be two possible mechanisms to explain the 
growth-inhibition of melatonin analogue against cancer 
cells.
These results highlight that UCM 1037 mode of 
action is cell line dependent and the differences in cell 
types could underlie the lack of an apparent change in 
the apoptotic proteins in most cell lines as well as the 
different cell death processes observed. Since melatonin 
has the ability to exert its effects with or without a receptor 
and modulates many different pathways, melatonin 
analogue’s mechanisms are difficult to interpret and a 
complete understanding of how UCM 1037 exerts its 
antiproliferative and cytotoxic effects is still not well 
defined.
Furthermore, pro-apoptotic effects of  melatonin 
derivatives can be counter-intuitive, since high 
concentrations of melatonin have been shown to inhibit 
cell death and to protect normal cells against oxidative 
damage. However, we have observed that melatonin 
analogues can trigger cell death, both in cultured cancer 
cells and in vivo, suggesting that these molecules could 
enhance the effect of chemotherapeutic drugs.
In conclusion, novel melatonin analogues described 
in this paper demonstrated to be antiproliferative 
compounds with significant cytotoxic activity in 
melanoma and breast cancer cells. The anticancer 
effects of melatonin in many tumor cells have attracted 
considerable attention and the number of related studies 
is rapidly increasing [50]. The development of the new 
melatoninergic ligands which could be used both for 
scientific research and in medical practice is raising 
alongside [20]. The study of synergistic relationships 
between melatonin analogues and anti-cancer drugs is a 
promising field, and these compounds could significantly 
strengthen the cytostatic and the cytotoxic effects triggered 
by conventional antineoplastic drugs. 
MATERIALS AND METHODS
Melatonin analogues synthesis
The new melatonin analogues were prepared 
by O-alkylation of N-acetyl-5-hydroxytryptamine 
with 1-bromo-4-phenylbutane in the presence of 
sodium hydride (UCM 976) and subsequent C2-indole 
halogenation with phenyltrimethylammonium tribromide 
(UCM 1032) or with iodine and silver triflate (UCM 
1037). The 2-phenyl melatonin analogue (UCM 1033) was 
prepared from O-demethyl-2-phenylmelatonin (previoulsy 
obtained by ether cleavage of 2-phenylmelatonin using 
boron tribromide) and 1-bromo-4-phenylbutane in the 
presence of sodium hydride. 
The experimental synthetic procedures used 
to prepare the new melatonin analogues and their 
characterization are available as Supplementary Data.
Human melatonin receptors binding assay
The two radioligands, 2-[125I]iodomelatonin 
(specific activity, 2000 Ci mmol−1) and [35S]GTPγS ([35S]
guanosine-5′-O-(3-thio-triphosphate), specific activity 
1000 Ci mmol−1, were purchased from PerkinElmer. 
Binding affinities were determined using 2-[125I]
iodomelatonin as the labeled ligand in competition 
experiments on cloned human MT1 and MT2 receptors 
expressed in NIH3T3 mouse fibroblast cells [51–53]. 
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Cell membranes were incubated for 90 min at 37°C in 
binding buffer (Tris-HCl, 50 mM, pH 7.4). The final 
membrane concentration was 5–10 μg of protein per 
tube. The membrane protein level was determined in 
accordance with a previously reported method [54]. 2-[125I]
Iodomelatonin (100 pM) and different concentrations of 
melatonin (10–10–10–6 M) or of the melatonin analogues 
were incubated with the receptor preparation for 90 min 
at 37 °C. Nonspecific binding was assessed with 10 μM 
melatonin; IC50 values were determined by nonlinear 
fitting strategies with the program PRISM (GraphPad 
SoftWare Inc., San Diego, CA, USA). The pKi values 
were calculated from the IC50 values in accordance with 
the Cheng–Prusoff equation [55]. The pKi values are 
the mean of at least three independent determinations 
performed in duplicate.
To define the functional activity of the melatonin 
analogues at MT1 and MT2 receptor subtypes, [
35S]GTPγS 
binding assays in NIH3T3 cells expressing human-cloned 
MT1 or MT2 receptors were performed. The amount 
of bound [35S]GTPγS is proportional to the level of the 
analogue-induced G-protein activation and is related to 
the intrinsic activity of the compound under study. The 
detailed description and validation of this method were 
reported elsewhere [51, 56]. Membranes (15–25 μg of 
protein, final incubation volume 100 μL) were incubated 
at 30°C for 30 min in the presence and in the absence of 
melatonin analogues in an assay buffer consisting of [35S]
GTPγS (0.3–0.5 nM), GDP (50 μM), NaCl (100 mM), and 
MgCl2 (3 mM). Nonspecific binding was defined using 
[35S]GTPγS (10 μM). In cell lines expressing human MT1 
or MT2 receptors, melatonin produced a concentration 
dependent stimulation of basal [35S]GTPγS binding with 
a maximal stimulation, above basal levels, of 370% and 
250% in MT1 and MT2 receptors, respectively. Basal 
stimulation is the amount of [35S]GTPγS specifically 
bound in the absence of compounds, and it was taken as 
100%. The maximal G-protein activation was measured 
in each experiment by using melatonin (100 nM). 
Compounds were added at three different concentrations 
(one concentration was equivalent to 100 nM melatonin, 
a second one 10 times smaller, and a third one 10 times 
larger), and the percent stimulation above basal was 
determined. The equivalent concentration was estimated 
on the basis of the ratio of the affinity of the test 
compound to that of melatonin. It was assumed that at the 
equivalent concentration the test compound occupies the 
same number of receptors as 100 nM melatonin. All of the 
measurements were performed in triplicate. The relative 
intrinsic activity (IAr) values were obtained by dividing 
the maximum ligand-induced stimulation of [35S]GTPγS 
binding by that of melatonin as measured in the same 
experiment. By convention, the natural ligand melatonin 
has an efficacy (Emax) of 100%. Full agonists stimulate [
35S]
GTPγS binding with a maximum efficacy, close to that of 
melatonin itself. If Emax is between 30% and 70% that of 
melatonin (0.3 < IAr < 0.7), the compound is considered 
a partial agonist, whereas if Emax is lower than 30% (IAr < 
0.3), the compound is considered an antagonist [57].
Cell culture and reagents
Human MT1 and MT2 receptors were stably 
transfected into NIH3T3 mouse fibroblast cells as 
previously described [52, 53]. Briefly, full-length cDNAs 
coding for melatonin receptors, cloned from human 
cerebellum [51], were subcloned into pcDNA INeo 
(Invitrogen, San Diego, CA, USA) and used to transfect 
NIH3T3 mouse fibroblast cells by using liposomal 
transfection kit DOTAP (Boehringer Mannheim, New 
York, NY, USA), according to the manufacturer’s 
instructions. Selection with G418 (1 mg/ml) started 
48 hours after transfection. Stably transfected NIH3T3 
cells expressing human cloned MT1 (NIH3T3-1A) or 
MT2 (NIH3T3-1B) were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Euroclone, Milan, Italy) 
containing high glucose, 10% bovine calf serum, 1 mM 
sodium pyruvate and 1 mg /ml G418. Human breast 
cancer cell lines MCF-7 and MDA-MB231, obtained from 
American Type Culture Collection (Manassas, VA, USA) 
were propagated in RPMI 1640 medium (Euroclone, 
Milan, Italy), supplemented with 10% fetal bovine serum 
(Opticlone, Euroclone, Milan, Italy), 2 mM L-Glutamine 
and 100 U/100 µg/ml and Penicillin/Streptomycin. Human 
melanoma DX3 cells, obtained from dr. A.P. Albino 
(Memorial Sloan Kettering Cancer Center, New York, NY, 
USA), and WM-115 cells, obtained from American Type 
Culture Collection (Manassas, VA, USA), were cultured 
in DMEM high glucose, supplemented with 10% of fetal 
bovine serum, 2 mM L-Glutamine and 100 U/100 µg/ml of 
Penicillin/Streptomycin. All cells were incubated at 37°C 
with 5% CO2 humidified atmosphere. Melatonin was 
purchased from Sigma-Aldrich (Milan, Italy).
Cellular proliferation and viability assay
MCF-7, MDA-MB231, WM-115 and DX3 cells 
were seeded in 96-well plates at 5.5 × 103, 3 × 103, 7 × 103, 
5 × 103 cells/well, respectively and incubated at 37°C with 
5% CO2 humidified atmosphere. 24 hours later, cells were 
treated with 0.1% DMSO dissolved in culture medium or 
with different doses of melatonin, UCM 976, UCM 1032, 
UCM 1033 and UCM 1037 diluted in 0.1% DMSO and 
cultured for 24, 48 and 72 hours. 
The cell viability and proliferation were assayed 
using the XTT Cell Viability Assay Kit (Cell Signaling, 
Euroclone, Milan, Italy), according to the manufacturer’s 
protocol. Briefly, cells were incubated for three hours with 
freshly prepared XTT solution (50 µL/well) and then the 
number of viable cells was assessed by measuring the 
absorbance at 450 nm. The experiments were performed 
in quadruplicate and repeated three times. 
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Apoptosis assay
DX3, WM-115, MCF-7 and MDA-MB231 cells 
were seeded in 60-mm plates and incubated at 37°C with 
5% CO2 humidified atmosphere. 24 hours later, cells were 
treated with 0.1% DMSO dissolved in culture medium or 
with 10−4 M UCM 1037 diluted in 0.1% DMSO. After 24, 
48 and 72 hours  cells were simultaneously stained with 
Alexa Fluor 488-conjugated Annexin-V and PI, using the 
Vybrant Apoptosis Assay kit #2 (Molecular Probes, USA), 
according to the manufacturer’s instructions. Samples 
were analyzed by FACScalibur flow cytometer (Becton 
Dickinson Biosciences, San Jose, CA, USA). In each 
analysis 10,000 events were recorded and the percentage 
of apoptotic cells estimated by means of the CellQuest Pro 
software (Becton Dickinson). The simultaneous staining of 
cells with Annexin-V and Propidium Iodide (PI) allowed 
the resolution of viable cells (A−/PI−), early apoptotic 
cells (A+/PI−), necrotic cells (A−/PI+) and late apoptotic 
cells (A+/PI+).
Animal experiments
Eight-week-old Swiss male nude mice weighing 
22–24 g were purchased from Charles River Laboratory 
(Calco, Italy). All procedures involving mouse care were 
in compliance with international directives (directive 
2010/63/EU of the European parliament and council; 
Guide for the Care and Use of Laboratory Animals, 
United States National Research Council, 2011) and the 
experimental protocols were authorized by the Committee 
on Ethics in Animal Experiments of the Italian Minister 
of Health. Mice were fed a normal mouse diet ad libitum 
and were housed under biosafety level 2 conditions. 
Experiments were performed under barrier conditions, 
and sentinel mice were monitored by a quality assurance 
program. 
In each experiment 24 nude mice were injected 
subcutaneously (s.c.) into the right flank with 1 × 106 
human DX3 melanoma cells/mouse. The tumors were 
allowed to grow for 7 days and when the tumors were 
detectable, animals were randomly divided into 4 groups 
(6 mice/group) and treated (s.c. administration) every day 
with 5% DMSO (control group), UCM 1037, UCM 1033 
and melatonin, used at the dose of 16 mg /Kg diluted in 5% 
DMSO. After 4 weeks from cell injection, all animals were 
sacrificed and tumors removed and weighted. Experiments 
were completed three times with similar results. 
Western blot analysis
3 × 105 DX3, WM-115, MCF-7 and MDA-MB231 
cells were seeded in 60-mm plates and incubated at 37°C 
with 5% CO2 humidified atmosphere. 24 hours later, 
cells were treated with 0.1% DMSO dissolved in culture 
medium or with 10−4 M UCM 1037 diluted in 0.1% 
DMSO and cultured for 10, 30, 60, 120, 240 minutes. 
Cells were collected by centrifugation at 1000 rpm for 10 
min, washed with cold PBS, resuspended in lysis buffer 
(50 mM Hepes-NaOH, pH 7.5, 150 mM NaCl, 15 mM 
MgCl2, 1 mM EGTA-NaOH pH7.5, 1% Triton X-100, 
1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, and 10 μg/ml of leupeptin, aprotinin, antipain, 
and chymostatin) and incubated on ice for 45 min. The 
lysates were centrifuged at 13,000 rpm for 10 min at 4°C. 
Equivalent amounts of proteins were analyzed by SDS–
polyacrylamide gel electrophoresis. After electrophoretic 
separation, the proteins were transferred onto nitrocellulose 
membrane (GE Healthcare, Pittsburg, PA, USA). After 1 hr 
of incubation in blocking solution (5% milk in PBS), filters 
were incubated with the appropriate antibodies: Mel-1A/
B-R, Bcl-2 (Santa Cruz Biotechnology, Dallas, TX, USA), 
Ser473 phosphorylated Akt (p-Akt), Akt,  Thr202/Tyr204 
phosphorylated p44/p42 MAPK (p-MAPK), MAPK, 
caspase 3 (Cell Signaling Technology, MA, USA) and 
α-Tubulin (Sigma-Aldrich). Proteins were visualized with 
peroxidase-coupled secondary antibody (GE Healthcare), 
using enhanced chemiluminescence (ECL) for detection 
(GE Healthcare). Densitometry was performed on scanned 
immunoblot images using the NIH ImageJ software.
Statistical analysis
All results were expressed as mean ± standard 
deviation (s.d.). The significance of differences was 
evaluated with ANOVA and Bonferroni’s test. A probability 
level of P <0.05 was considered statistically significant.
Abbreviations
MT1, melatonin receptor 1; MT2, melatonin 
receptor 2; CREB, cAMP response element-binding 
protein; MAPK1/2, mitogen-activated protein kinase 
1/2; ERK1/2, extracellular signal–regulated kinase 1/2; 
PLC, phospholipase C; PKC, protein kinase C; PI3K, 
phosphatidylinositol 3 kinase; DMSO, dimethyl sulfoxide; 
[35S]GTPγS, [35S]guanosine-5′-O-(3-thio-triphosphate); 
IAr, relative intrinsic activity; PI, Propidium Iodide; p-Akt, 
Ser473 phosphorylated Akt; p-MAPK, Thr202/Tyr204 
phosphorylated p44/p42 MAPK; ANOVA, analysis of 
variance; s.d., standard deviation; MLT, melatonin.
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